The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Our Flavivirus Reagents

The Native Antigen Company offers an extensive range of antigens, antibodies, virus-like particles and cell-surface receptors for the flaviviruses, suitable for a range of research and development applications.



The flaviviruses are a diverse genus of positive-sense RNA viruses, largely transmitted by athropod vectors, such as mosquitos and ticks. The emergence and global spread of flaviviruses in recent decades has been remarkable, with around 400 million human infections of dengue virus each year. Due to the similarities of flaviviral structural antigens and the serological responses they elicit, the development of flaviviral diagnostics and vaccines present unique challenges.

Our Reagents

To support flavivirus research and development, The Native Antigen Company offers an extensive range of reagents, including native and recombinant antigens, virus-like particles, antibodies and immunoassays.

  • Our NS1 proteins are produced in their hexameric form and are glycosylated and folded like native antigens, with research groups having demonstrated their functional activity.
  • Our virus-like particles comprise Envelope and prM/M proteins, are non-infectious, and demonstrate antigenic similarity to native viral particles.
  • To complement our NS1 proteins and VLPs, we offer soluble Envelope proteins for use in the development of serological diagnostic assays.

For more information on each of our flavivirus offerings, click the buttons below:

Dengue Virus

For Dengue virus, we offer:

    • 40 antigens
    • 27 antibodies
    • 5 virus-like particles
    • 3 ELISAs

Hepatitis C Virus

For Hepatitis C virus, we offer:

    • 1 antigen
    • 18 antibodies

Japanese Encephalitis Virus

For Japanese Encephalitis virus, we offer:

    • 4 antigens
    • 10 antibodies
    • 1 virus-like particle
    • 2 donor sera

Powassan Virus

For Powassan virus, we offer:

    • 1 antigen
    • 5 antibodies

Saint Louis Encephalitis Virus

For Saint Louis Encephalitis virus, we offer:

    • 2 antigens

Tick-Borne Encephalitis Virus

For Tick-Borne Encephalitis virus, we offer:

    • 5 antigens
    • 6 antibodies
    • 3 ELISAs

Usutu Virus

For Usutu virus, we offer:

    • 1 antigen

Wesselsbron Virus

For Wesselsbron virus, we offer:

    • 1 antigens

West Nile Virus

For West Nile virus, we offer:

    • 6 antigens
    • 7 antibodies

Yellow Fever Virus

For Yellow Fever virus, we offer:

    • 6 antigens
    • 2 antibodies
    • 6 donor sera

Zika Virus

For Zika virus, we offer:

    • 12 antigens
    • 13 antibodies
    • 1 virus-like particle
    • 1 ELISA

Virus Receptors

To support fundamental research into flavivirus pathogenesis and serology, we also offer a range of human flavivirus receptors:

Need to Get in Touch?

Would you like to be kept informed of the latest news and innovations from the infectious disease community? Please let us know if you would like us to contact you or not by selecting one of the options below.

14 + 6 =

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

New antigens support research into BA.5 variant, currently responsible for over half of global COVID-19 cases Oxford, UK, 02 November 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables...

The Role of Serology in Tracking COVID-19 Mutations

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...

Preparing for Disease Y: A Better Serological Toolbox

This article was originally published on Clinical Lab Manager. It’s been over a year since the World Health Organization (WHO) declared COVID-19 a pandemic. SARS-CoV-2 has since infected 200 million people, resulting in nearly 4 million deaths and substantial economic...

Keeping Up with the New SARS-CoV-2 Variant Nomenclature

If you’ve been struggling to make sense of SARS-CoV-2 variant nomenclature, you’re not alone. Due to the existence of multiple genomic sequence databases, various naming systems are in use for the rapidly growing range of SARS-CoV-2 variants of concern/interest. In a...

Making Sense of the SARS-CoV-2 Spike Mutations

Through much of 2020, SARS-CoV-2 accumulated mutations at a steady, yet unspectacular rate. However, as global cases approached 100 million by the end of the year, multiple variants began to emerge. Exhibiting more considerable genomic changes, some variants have...

D614G: Putting the Mutation in Perspective

Since the emergence of SARS-CoV-2, scientists have speculated about the risks of mutation and what this could mean for therapeutics and vaccines. In this blog, we explore the nature viral mutation, what is known about the D614G mutant of SARS-CoV-2, and introduce our...

The Endemic Coronaviruses and What They Might Tell us About COVID-19

While less-well known than some of their counterparts, the 229E, NL63, OC43, and HKU1 human coronaviruses are a significant cause of respiratory disease worldwide. The evolutionary histories and host associations of the endemic coronaviruses also provide important...

Q&A: An Insight Into COVID-19 Serology

During the course of the current coronavirus pandemic, we have all been aware of the urgent need for nucleic acid testing to identify people currently infected with SARS-CoV-2. The second form of testing needed are serological immunoassays, which can identify past...

A Q&A with David Flavell of Leukaemia Busters

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in the...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

Designing for Differentiation: Why We Need Highly Specific Diagnostics for a COVID-19 Vaccine

Assessment of vaccine-induced immune responses in clinical trials will require highly specific diagnostic assays to ensure safety. This blog was originally published on Clinical Lab Manager.The Vaccine Race Vaccines are the most effective means of preventing...

An Early Look at Vaccines for COVID-19

In the first of a three-part series on the design, immunology and manufacture of COVID-19 vaccines, we take an early look at the major technologies under development and weigh-up the challenges these vaccines will face in reaching late-phase clinical trials.Why We...

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

Coronaviruses: The Next Disease X?

For much of their known history, the coronaviruses were regarded as relatively benign pathogens with little potential to cause human harm. However, the emergence of SARS and MERS in recent decades has brought coronaviruses into the global spotlight. In this blog we...